EMORY INTEGRATED PROTEOMICS SHARED RESOURCE PROJECT SUMMARY / ABSTRACT The mission of the Emory Integrated Proteomics Shared Resources (Proteomics SR) is to provide protein analytical services using cutting-edge mass spectrometry (MS) in support of Winship Cancer Institute. The main technology platform of Proteomics SR is liquid chromatography coupled with tandem mass spectrometry (LC- MS/MS) for highly sensitive identification and quantification of proteins and their post-translational modifications (PTMs). Proteomics SR is a critical technological resource for Winship investigators and has supported a broad range of cancer projects related to cancer cell biology, genetics, epigenetics, and novel therapeutics. The primary aims of the of Proteomics SR are to provide: (1) access to state-of-the-art mass spectrometry for both discovery and targeted proteomic applications, (2) provide consultation, expert training, and support for proteomics-related research projects, and (3) provide infrastructure and resources that advance collaborative multidisciplinary research and innovation among Winship investigators. Collectively, these aims will lead to an increase in the quality of proteomics data available to Winship investigators through experimental design optimization and proper interpretation. The mass spectrometry technologies provided are vital to Winship researchers and key findings from these proteomic studies are fundamental to Winship's efforts to improve the prevention, detection, and treatment of human cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA138292-11
Application #
9685140
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-04-01
Budget End
2020-03-31
Support Year
11
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Goldstein, Jordan S; Nastoupil, Loretta J; Han, Xuesong et al. (2018) Disparities in survival by insurance status in follicular lymphoma. Blood 132:1159-1166
Richardson, Alessandra M; Havel, Lauren S; Koyen, Allyson E et al. (2018) Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell-Cancer-Associated Fibroblast Interactions during Collective Invasion. Clin Cancer Res 24:420-432
Jin, Lingtao; Chun, Jaemoo; Pan, Chaoyun et al. (2018) MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. Cancer Cell 34:315-330.e7
Guidot, Daniel M; Switchenko, Jeffrey M; Nastoupil, Loretta J et al. (2018) Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. Leuk Lymphoma 59:888-895
Chowdhary, Mudit; Okwan-Duodu, Derick; Switchenko, Jeffrey M et al. (2018) Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery. J Neurooncol 136:289-298
Chen, Zhengjia; Zheng, Youyun; Wang, Zhibo et al. (2018) Interactive calculator for operating characteristics of phase I cancer clinical trials using standard 3+3 designs. Contemp Clin Trials Commun 12:145-153
Halani, Sameer H; Yousefi, Safoora; Vega, Jose Velazquez et al. (2018) Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways. NPJ Precis Oncol 2:24
Ferris, Matthew J; Liu, Yuan; Ao, Jingning et al. (2018) The addition of chemotherapy in the definitive management of high risk prostate cancer. Urol Oncol 36:475-487
Halicek, Martin; Little, James V; Wang, Xu et al. (2018) Deformable Registration of Histological Cancer Margins to Gross Hyperspectral Images using Demons. Proc SPIE Int Soc Opt Eng 10581:
Cassidy, Richard J; Switchenko, Jeffrey M; El-Deiry, Mark W et al. (2018) Disparities in Postoperative Therapy for Salivary Gland Adenoid Cystic Carcinomas. Laryngoscope :

Showing the most recent 10 out of 331 publications